Heart Scan to Check Coronary Artery Disease in People With Chronic Kidney Disease
Studies a heart scan measuring blood flow in adults with chronic kidney disease.
Key facts
- Who runs it
- University Hospital, Grenoble
- Where
- La Tronche, FranceSee the site
- Trial code
- Registry title
- Coronary Artery Disease Screening in Patients With Chronic Kidney Disease
- Status
- Not yet recruiting
- People taking part
- 283 people, planned
- Started
- 1 Jun 2026
- Expected to end
- 31 Jan 2028
- Type of study
- Observational
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease who are already having a CZT-SPECT heart scan with coronary flow reserve measurement as part of their normal care.
- Age
- Over 18 years
- Sex
- Women and men can join.
- Disease stage
- Chronic kidney disease at renal risk: GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g.
- Earlier treatment
- The CZT-SPECT heart scan must be done as part of standard care, decided by the doctor and not because of the study.
- Biomarker or test result
- Kidney function (GFR) and albuminuria levels as listed above.
Main reasons for not taking part
- Legally protected adults
- People deprived of liberty
- Pregnant women
- People with a normal coronary exploration within the past year
- People not affiliated with the French social security system
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female patients aged over 18 years
- Affiliated with the French social security system
- Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
- Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
- Having expressed no objection to participation in this study
Who cannot take part
- Legally protected adult (Article L1121-8 of the French Public Health Code)
- Person deprived of liberty (Article L1121-8 of the French Public Health Code)
- Pregnant woman
- Patient who has undergone a normal coronary exploration within the past year
Where in France
- Chu Grenoble AlpesLa Tronche, FranceContact: Gilles Barone Rochette, PINo longer taking part
About the trial
What the trial wants to find out
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease
- Plain-language title
- Heart Scan to Check Coronary Artery Disease in People With Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 May 2026